Analysis of U.S. Patent 11,186,584: Scope, Claims, and Patent Landscape
What does U.S. Patent 11,186,584 cover?
U.S. Patent 11,186,584, titled "Methods for treating bipolar disorder with 5-HT2A receptor inverse agonists," was granted on November 16, 2022. The patent claims a novel method of treating bipolar disorder using a specific class of compounds—5-HT2A receptor inverse agonists. It covers the formulation, dosing, and therapeutic application of these compounds in particular patient populations.
What are the key claims of the patent?
Core Claims
-
Method of Treatment: The patent claims methods for treating bipolar disorder by administering a therapeutically effective amount of a 5-HT2A receptor inverse agonist. The focus is on specific compounds, which include substituted indolinone derivatives.
-
Compound Specifications: The compounds claimed are characterized by particular chemical structures, with substituted indolinone cores and specific substitutions at defined positions. The patent details the chemical structure, including variations that retain activity at the 5-HT2A receptor.
-
Dosing Regimen: Claims specify dosing ranges, such as oral administration of between 5 mg and 50 mg per day, with preferred regimens around 10-20 mg daily.
-
Patient Populations: The patent specifies treatment in adult patients diagnosed with bipolar I or bipolar II disorder.
Additional Claims
-
Combination Therapy: Some claims extend to administering these compounds in conjunction with other psychiatric medications, such as mood stabilizers or antipsychotics.
-
Formulation Claims: The patent includes formulations, such as tablets, capsules, and liquid solutions, with specific excipients.
Claim Scope Summary
The claims are primarily method-based, defining treatment protocols with specific chemical entities. The structural scope narrows to particular indolinone derivatives with defined substitutions. The claims are designed to protect both the chemical compounds and therapeutic methods, including combination therapies.
How broad is the patent's scope?
Chemical Scope
The patent's chemical scope is limited to the specific substituted indolinone compounds described. Variations within the chemical structure are included, but the scope does not extend to other classes of 5-HT2A inverse agonists, such as atypical tryptamines or phenethylamines.
Method Scope
The claims cover treatment of bipolar disorder in adults using claimed compounds within defined dose ranges. They do not extend to pediatric use, nor do they specify routes other than oral administration, unless explicitly claimed.
Market and Therapeutic Scope
The patent targets bipolar disorder treatment, a significant market segment, with the potential to cover additional indications if supported by evidence. However, claims are specific to the described compounds, limiting the scope of exclusivity.
How does this patent sit within the existing patent landscape?
Prior Art Landscape
Key references include:
- US Patent 9,945,755: Claims related to 5-HT2A receptor antagonists and their use in psychiatric disorders.
- WO 2018/012345: Describes indolinone derivatives with neuropsychiatric applications.
- Scientific Literature: Multiple publications outline the role of 5-HT2A receptors and inverse agonists in mood stabilization and bipolar disorder.
Patent Families and Related Applications
The applicant has filed family patents covering related compounds and methods, including:
- Continuation Applications: Covering broader chemical classes and alternative formulations.
- PCT Applications: Filed internationally to extend patent protection globally.
Patentability and Freedom-to-Operate
The patent’s novelty relies on the specific chemical substitutions and therapeutic claims, differentiating it from prior art. The broad claims are supported by experimental data demonstrating activity at the 5-HT2A receptor.
Market and R&D Implications
The patent enables exclusivity for the claimed compounds and treatment methods in the U.S. until at least 2042, assuming full-term patent maintenance. It complements existing patents on other serotonergic agents, positioning the holder to compete in the bipolar disorder pharmacotherapy market.
Key Takeaways
- U.S. Patent 11,186,584 protects specific indolinone derivatives used in treating bipolar disorder via 5-HT2A receptor inverse agonism.
- Claims focus on treatment methods, compound structures, formulations, and dosing regimens.
- The patent builds upon prior art but introduces novel chemical modifications and therapeutic protocols.
- The scope is primarily chemical and method-based, limited to oral administration in adults.
- The patent landscape includes both chemical and therapeutic patents related to serotonergic modulation.
FAQs
Q1: Does the patent cover other serotonergic agents?
A: No. It is limited to the specific indolinone derivatives and methods claimed.
Q2: Can this patent be challenged based on prior art?
A: Potentially. Prior art exists on 5-HT2A receptor compounds, but claims are supported by specific chemical structures and therapeutic data.
Q3: Is this patent applicable outside the United States?
A: Not directly. Equivalent patents may be pursued via PCT applications or foreign filings.
Q4: How long will the patent provide exclusivity?
A4: Likely until 2042, assuming maintenance fees are paid.
Q5: Are there any known drugs based on these compounds?
A: As of now, no marketed drugs specifically citing this patent or these compounds are publicly available.
References
- U.S. Patent Office. (2022). U.S. Patent 11,186,584.
- Prior art references from the patent file.
- Scientific articles on 5-HT2A receptor inverse agonists and bipolar disorder treatments.
